# Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

> **NCT02695121** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2133575 (actual)

## Conditions studied

- Breast Cancer
- Bladder Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02695121
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-01
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-01-30
- **Target enrollment:** 2133575 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02695121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02695121, "Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02695121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*